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Chapter 4
Unusual reduction of the in vitro permeation of
[3H]dexetimide by atropine
4.0. Summary
The influence of atropine on the permeation of [3H]dexetimide is studied using fresh
and frozen pig epidermal membranes and artificial membranes (Silastic®). In
previous experiments with fresh pig epidermal membranes, [3H]dexetimide was used
as an internal standard to correct for variations in the skin. However, we noticed
that in the presence of atropine the permeation of [3H]dexetimide decreased whereas
no influence was seen using other anticholinergics, including atropine sulphate. We
also noticed that the ratios became constant for all anticholinergics, except for
atropine. To investigate whether this effect is caused by atropine or by the type of
membrane, experiments with frozen epidermal membranes and Silastic® membranes
were performed.
The experiments show that atropine reduces the permeation of [3H]dexetimide
through fresh as well as frozen pig epidermal membranes. This decrease in
permeation also occurs with Silastic® membranes, however to a lesser extent. This
seemed to suggest that the transepidermal routes for atropine and [3H]dexetimide are
different and that some interaction between the two drugs may occur at the surface
of the membrane. However, it should be noted that atropine sulphate did not affect
the permeation of [3H]dexetimide. Because this contradicts the above hypotheses,
further studies are necessary. These results show that one should remain aware of




To measure the in vitro permeation of seven anticholinergics, we developed a
standardization procedure to correct for the large variations in permeability between
skin samples (Chapter 3). Radiolabelled [3H]dexetimide was added to the donor
solution as an internal standard and ratios were calculated by dividing the
percentage of permeated anticholinergic by the percentage of permeated
[3H]dexetimide. For all anticholinergics studied, the use of ratios decreased the
variations which showed the usefulness of an internal standard to correct for
variations in the skin. However, we noticed that in the presence of atropine the
permeation of [3H]dexetimide decreased substantially compared to the
[3H]dexetimide permeation in the presence of the other anticholinergics, including
atropine sulphate.
Therefore, we studied the influence of atropine on the permeation of [3H]dexetimide
in more detail in this chapter. Experiments were performed using a donor solution
of [3H]dexetimide with or without atropine, and using three types of membranes.
The tested membranes were fresh and frozen pig epidermal membranes, and
artificial membranes (Silastic®). Pig skin was chosen because it has histological
properties and permeabilities comparable to human skin, and Silastic® was used as
a synthetic alternative to skin [1-18].
4.2. Materials and Methods
4.2.1. Materials
[3H]Dexetimide hydrochloride ([3H]dex, 15 Ci/mmol) was obtained from Janssen
Pharmaceutica N.V.(Beerse, Belgium). Atropine base was obtained from Merck
(Darmstadt, Germany). Dexetimide hydrochloride was of pharmaceutical quality and
obtained from a local wholesaler. 1-Dodecylazacycloheptan-2-one (Azone®) was
kindly supplied by Nelson Research (Irvine, CA, USA). Sigmacoat® was obtained
from Sigma (St.Louis, MO, USA). Propylene glycol was purchased from Brocacef
(Maarssen, The Netherlands). All other chemicals and solvents were of analytical
grade and obtained from Merck (Darmstadt, Germany).
4.2.2. Preparation of solutions
Isotonic phosphate buffered saline pH 7.4 (PBS-buffer) was prepared by dissolving
8.00 g NaCl, 0.20 g KCl, 0.20 g KH2PO4 and 1.44 g Na2HPO4.2H2O in 1 l distilled
water. PBS-buffer was used as the receptor solution.
Ethanol / propylene glycol / PBS-buffer / Azone® 60:20:15:5 (v/v) was used as
donor solution (vehicle) [19].
Drug solutions with atropine or unlabelled dexetimide were prepared by mixing 500
µl of a solution of atropine or unlabelled dexetimide (15 mg/ml in vehicle) with 10
µl of an ethanolic stock solution of [3H]dex (3 MBq/ml).
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The drug solution without atropine or unlabelled dexetimide was prepared by
mixing 500 µl vehicle with 10 µl of an ethanolic stock solution of [3H]dex
(3 MBq/ml).
4.2.3. Preparation of pig skin
Pigs (CDL, Groningen, The Netherlands) weighing 20 kg, 8 weeks old, previously
used for experimental surgery and sacrificed by termination of the resuscitation,
were used. Pig ears were obtained within 30 min after termination of the
resuscitation and cleaned under cold running water before whole skin membranes
were removed from the underlying cartilage. Hairs were cut and the whole
membranes were used immediately (fresh skin) or frozen in liquid nitrogen and
stored at -80°C until further use (frozen skin). Epidermal membranes were prepared
by soaking the whole skin membranes in water for 120 sec at 60°C, followed by
blunt dissection [7, 15]. The frozen whole membranes were thawed before
epidermal membranes were prepared.
4.2.4. Preparation of Silastic® membranes
Non-reinforced silicone membrane (Silastic®, polydimethyl siloxane, type 500-1,
Laboratoire Perouse Implant, Bornel, France) of 0.125 mm thickness was
extensively rinsed in hot distilled water (60°C) until all sodium bicarbonate (present
on the surface to facilitate handling) was removed. This was followed by a thorough
rinse in distilled water (20°C) for one hour [17].
4.2.5. Permeation experiments
Permeation experiments were performed using Franz diffusion cells [16, 20, 21].
These cells were made of glass with a contact area of 1.35 cm2 (University Centre
for Pharmacy, Groningen, The Netherlands) and pretreated with a silanizing agent
(Sigmacoat®). The Franz diffusion cell consists of a donor compartment and a
receptor compartment. The membranes were mounted between the cell
compartments with the stratum corneum towards the donor compartment and an
O-ring was used to position the membrane. The two cell compartments were held
together with a clamp. The receptor compartment has a volume of 4.3 ml and was
filled with PBS-buffer. It was kept at 37°C by circulating water through an external
water jacket. After 30 min of equilibration of the membrane with the receptor
solution, 200 µl of the drug solution was applied in the donor compartment by
means of a pipet. The donor compartment was covered with parafilm to prevent
evaporation of the solvent. The receptor fluid was continuously stirred by means of
a spinning bar magnet, at 400 rpm (Multipoint HP 15, Variomag, München,
Germany). Receptor solution samples, 2.0 ml aliquots, were withdrawn through the
sampling port of the receptor compartment at various time intervals and stored at -
20°C until analysis. The cells were refilled with receptor
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Table 4.1. Permeation of [3H]dexetimide through fresh pig epidermal membranes in
the absence and presence of atropine.









































































*1 Permeation experiments in the absence of atropine but in the presence of dexetimide: n=3.
*2 Permeation experiments in the presence of atropine: n=4.
Figure 4.1. Permeation of [3H]dexetimide through fresh pig epidermal membranes in
the presence of atropine or dexetimide; each point represents the mean and
standard error of the mean.
= [3H]dex in the presence of dexetimide (n=3); = [3H]dex in the
presence of atropine (n=4).
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solution to keep the volume constant during the experiment. The experiments were
run for 25 hours. The amounts of [3H]dexetimide and atropine or dexetimide present
in the receptor solution, were measured by liquid scintillation counting and
radioreceptor assay under equilibrium conditions, respectively, according to
previously described procedures (Chapter 3).
4.3. Results and Discussion
Figure 4.1 shows the mean cumulative percentage permeation of radiolabelled
[3H]dexetimide through fresh pig epidermal membranes in the presence of atropine
or dexetimide, respectively. During steady state which is reached after
approximately 17 hours, the permeation of [3H]dexetimide in the presence of
atropine is about a factor 3 lower in comparison with the [3H]dexetimide permeation
in the presence of dexetimide (Table 4.1). This decrease was only observed with
atropine and not with the other tested anticholinergics (atropine sulphate
monohydrate, benztropine mesylate, dexetimide hydrochloride, oxyphencyclimine
hydrochloride, scopolamine hydrobromide trihydrate, tropicamide). We also noticed
that the ratios, calculated by dividing the percentage of permeation of
anticholinergic by the permeation of the internal standard [3H]dexetimide, became
constant for all anticholinergics after 15 hours, except for atropine (Chapter 3)
which seems to indicate that the permeation routes of atropine and [3H]dexetimide
are different (Table 4.1). If so, [3H]dexetimide would not be appropriate to serve as
an internal standard for atropine permeation studies. To investigate these phenomena
further, we performed in vitro experiments with frozen pig epidermal membranes
and Silastic® membranes as well.
The permeation of [3H]dexetimide through frozen pig epidermal membranes in the
absence and presence of atropine is presented in Figure 4.2 and Table 4.2. Again,
the permeation of [3H]dexetimide decreased about a factor 3 in the presence of
atropine whereas no influence was seen using other anticholinergics, as shown in
Figure 4.3 for dexetimide. Apparently, storage of pig skin for 2 months at -80°C
resulted in a higher permeability compared to fresh epidermal membranes, which is
probably caused by a loss of barrier function of the skin and changes in physical
and chemical properties [22-25]. These results indicate that although the properties
of the skin may be altered due to freezing and thawing, the unusual behaviour of
[3H]dexetimide in the presence of atropine still exists.
Figure 4.4 shows the influence of atropine on the permeation of [3H]dexetimide
using Silastic® membranes. In the presence of atropine the permeation of
[3H]dexetimide is decreased, however the influence of atropine is small compared to
the results with pig epidermal membranes: After 17 hours the decrease of
[3H]dexetimide permeation in the presence of atropine is only about a factor 1.4.
It is generally assumed that most drugs permeate through biological membranes via
the transepidermal route, either through the intracellular spaces, or the intercellular
spaces, or through both (Chapter 1). In addition, there is the transappendageal
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Table 4.2. Permeation of [3H]dexetimide through frozen pig epidermal membranes in
the absence and presence of atropine.









































































*1 Permeation experiments in the absence of atropine: n=2.
*2 Permeation experiments in the presence of atropine: n=4.
*3 Significantly higher than [3H]dex permeation in the presence of atropine:
p < 0.05 (Student t-test).
Figure 4.2. Permeation of [3H]dexetimide through frozen pig epidermal membranes in
the absence and presence of atropine; each point represents the mean and
standard error of the mean.
= [3H]dex (n=2); = [3H]dex in the presence of atropine (n=4).
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Figure 4.3. Permeation of [3H]dexetimide through frozen pig epidermal membranes in
the absence and presence of dexetimide; each point represents the mean
and standard error of the mean.
= [3H]dex (n=2); = [3H]dex in the presence of dexetimide (n=4).
Figure 4.4. Permeation of [3H]dexetimide through Silastic® membranes in the absence
and presence of atropine; each point represents the mean and standard
error of the mean.
= [3H]dex (n=6); = [3H]dex in the presence of atropine (n=6).
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Table 4.3. Permeation of [3H]dexetimide through Silastic® membranes in the absence
and presence of atropine.



























































































*1 Permeation experiments in the absence of atropine: n=6.
*2 Permeation experiments in the presence of atropine: n=6.
*3 Significantly higher than [3H]dex permeation in the presence of atropine:
p < 0.01 (Student t-test).
*4 Significantly higher than [3H]dex permeation in the presence of atropine:
p < 0.01 (Mann-Whitney rank sum test).
route, but this route is considered of minor importance and only relevant for very
hydrophilic drugs [26, 27]. With Silastic® membranes which are considered to be
more hydrophobic than skin, only the more lipophilic transepidermal pathway is
mimicked [16, 26]. It can be noted from Table 4.3 that the permeation of
[3H]dexetimide alone through Silastic® membranes is comparable with the
permeation through fresh pig epidermal membranes. Yet, for atropine, permeation
through Silastic® membranes decreased by a factor 5 compared to the epidermal
membranes. This is in line with the more lipophilic character of dexetimide, and
may indicate that dexetimide preferably permeates via the more lipophilic
intercellular route whereas atropine permeates via the intracellular route. This
hypothesis seems to be corroborated by the finding that the ratio of atropine /
[3H]dexetimide does not become constant for fresh pig epidermal membranes
(Table 4.1).
However, the assumption of different pathways for atropine and [3H]dexetimide
does not explain the observation that atropine reduced the permeation of
[3H]dexetimide through epidermal membranes by a factor 3 and that the other
anticholinergics do not affect [3H]dexetimide permeation. This would suggest some
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sort of interaction between atropine and [3H]dexetimide at the membrane surface.
Competition for a common transport carrier may also be possible, but this would
imply common permeation routes, rather than different routes.
On the other hand, it should be noted that the experiments with atropine sulphate in
Chapter 3 showed that the permeation of [3H]dexetimide in the presence of atropine
sulphate did not reduce and that the ratio atropine sulphate / [3H]dexetimide was
constant at steady state. These results do not indicate an interaction or competition,
nor do they point to different permeation routes.
4.4. Conclusions
The experiments show that atropine reduces the permeation of [3H]dexetimide
through fresh and frozen pig epidermal membranes. This decrease in permeation
also occurs with Silastic® membranes, but to a lesser extent. The mechanism for
this phenomenon cannot be explained properly at this moment.
The results of the present studies show that care should be taken when dealing with
more than one drug in transdermal permeation studies. Also, it cannot be excluded
that vehicle components may interfere with the permeation of the active
ingredient(s).
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